Axsome Therapeutics, Inc. (NASDAQ:AXSM) General Counsel Hunter R. Murdock Sells 7,500 Shares

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) General Counsel Hunter R. Murdock sold 7,500 shares of the company's stock in a transaction on Friday, June 20th. The stock was sold at an average price of $102.47, for a total value of $768,525.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Hunter R. Murdock also recently made the following trade(s):

• On Monday, June 23rd, Hunter R. Murdock sold 6,014 shares of Axsome Therapeutics stock. The stock was sold at an average price of $100.12, for a total value of $602,121.68.
• On Tuesday, June 17th, Hunter R. Murdock sold 7,500 shares of Axsome Therapeutics stock. The stock was sold at an average price of $100.26, for a total value of $751,950.00.

Axsome Therapeutics Stock Performance

AXSM stock traded up $0.96 during mid-day trading on Monday, hitting $101.65. The company had a trading volume of 638,409 shares, compared to its average volume of 677,733. Axsome Therapeutics, Inc. has a 12-month low of $72.21 and a 12-month high of $139.13. The company has a quick ratio of 1.96, a current ratio of 2.03 and a debt-to-equity ratio of 3.48. The company has a 50-day moving average price of $106.72 and a 200 day moving average price of $107.16.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Cantor Fitzgerald upgraded Axsome Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th. Oppenheimer assumed coverage on Axsome Therapeutics in a research note on Tuesday, June 3rd. They issued an "outperform" rating and a $185.00 price objective for the company. Jefferies Financial Group started coverage on Axsome Therapeutics in a research note on Monday, April 7th. They issued a "buy" rating and a $200.00 price objective for the company. HC Wainwright restated a "buy" rating and set a $180.00 price objective on shares of Axsome Therapeutics in a research report on Tuesday, June 10th. Finally, Morgan Stanley raised their price objective on shares of Axsome Therapeutics from $125.00 to $190.00 and gave the company an "overweight" rating in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $172.33.

Institutional Trading of Axsome Therapeutics

Hedge funds have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd purchased a new stake in Axsome Therapeutics during the first quarter valued at $25,000. NBC Securities Inc. bought a new stake in shares of Axsome Therapeutics in the 1st quarter worth about $31,000. Quantbot Technologies LP bought a new stake in shares of Axsome Therapeutics in the 1st quarter worth about $31,000. AlphaQuest LLC purchased a new stake in shares of Axsome Therapeutics during the 1st quarter valued at about $38,000. Finally, Neo Ivy Capital Management bought a new position in shares of Axsome Therapeutics in the 1st quarter valued at about $41,000. Hedge funds and other institutional investors own 81.49% of the company's stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.